跳至主要内容
临床试验/NCT01826110
NCT01826110已完成1 期

"[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls"

Johns Hopkins University1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2013年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
21
试验地点
1
主要终点
Distribution Volumes of 11C-PIB

研究概览

简要总结

The purpose of this study is to investigate the radiotracer [11C] PIB in participants with probably Alzheimer's Disease (AD) and healthy age-matched controls.

详细描述

The objectives of the study are:

  1. To perform PET scans with [11C]PIB to use for direct (i.e., same-subjects) comparison of [11C]PIB and [18F]AV-45
  2. To establish the most effective and reliable PET imaging method to detect amyloid deposition in AD, in order to understand disease progression and subsequently evaluate treatment effects.
  3. To ascertain a PET imaging method that will minimize discomfort for subjects, thus increasing the potential for clinical follow-up scans, by reducing the patient burden and potential cost of future PET examinations.

A separate protocol/study will be conducted using [18F] AV-45. Participants who enroll in this protocol using [11C] PIB will be consented to participate in the [18F] AV-45 (IRB # NA_00033155) protocol/study as it is a mandatory requirement that participants participate in both protocols.Up to 20 participants with mild to moderate Alzheimer's Disease and 10 healthy volunteers will participate in this study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects at least 18 years of age
  • Subjects who in the opinion of the investigator based on medical history and physical exam can tolerate the PET scan procedures

排除标准

  • Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
  • Have current clinically significant cardiovascular disease.
  • Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse
  • Have a clinically significant infectious disease, including Acquired Immune Deficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) infection or previous positive test for hepatitis
  • Women of childbearing potential must not be pregnant (negative urine beta-hCG at the time of screening and negative urine beta-hCG on the day of imaging) or lactating at screening or at day of imaging
  • Have a history of relevant severe drug allergy or hypersensitivity (Relevant severe drug allergies should be determined by the PI, and any questions about a subject's eligibility can be directed to Avid. If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound
  • Have received an investigational medication within the last 30 days. Current clinically significant or unstable medical comorbidities, as indicated by history or physical exam
  • Have received a radiopharmaceutical for imaging or therapy within the past 7 days prior to the imaging session for this study
  • Body weight > 300 pounds
  • History of significant radiation exposure
  • Participants with pacemakers, implanted electronic hearing devices, aneurysm clips, shrapnel, unallowed prosthetic or other metallic device in their bodies
  • Pre-existing CNS disease (other than dementia), endocrine, or severe cardiovascular disease (MI, CABG, angioplasty)

研究组 & 干预措施

[11C]PIB

Experimental

[11C]PIB

干预措施: [11C]PIB (Drug)

结局指标

主要结局

Distribution Volumes of 11C-PIB

时间窗: Approximately 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

PET Imaging Study Using [11C]PIB in Subjects With AD... | 临床试验